Clinical trials: Apixaban, completed
Atrial Fibrillation
Non-Interventional Study Describing Direct Costs Related to Anti-coagulation Treatment
To describe the direct costs related to warfarin/apixaban treatment
- Trial name
- NCT04435769
- Where
- Czechia
- Volunteers
- 109 people
- Sponsor
- Pfizer
Acute Myocardial Infarction, Left Ventricular Thrombosis
Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus
Patients with acute ST-segment elevation myocardial infarction (STEMI) have an elevated risk of stroke, most of which are cardio-embolic in origin as a result of left ventricular (LV) thrombus formation.
- Conditions
- Acute Myocardial Infarction, Left Ventricular Thrombosis, Anticoagulants and Bleeding Disorders
- Trial name
- NCT03232398
- Testing
- Apixaban Oral Tablet [Eliquis], Warfarin
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Hadassah Medical Organization
Nephrotic Syndrome, Proteinuria
Pharmacokinetics of Apixaban in Nephrotic Syndrome
This study is to investigate the pharmacokinetics and pharmacodynamics of apixaban in nephrotic syndrome.
- Trial name
- NCT02599532
- Testing
- apixaban
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Cancer-associated Thrombosis
API-CAT STUDY for APIxaban Cancer Associated Thrombosis
The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non inferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent venous thromboembolism (VTE) in patients with…
- Trial name
- API-CAT (NCT03692065)
- Testing
- Apixaban 5 MG
- Where
- 114 sites in Austria, Belgium and 9 more
- Volunteers
- 1,766 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Healthy Volunteers
Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects
The purpose of this study is to assess the bioavailability of Apixaban solution administered through NGT and washed with Dextrose 5% in water (D5W) or infant formula relative to Apixaban solution administered orally in healthy…
- Trial name
- NCT02034578
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
A Phase III Study of Apixaban in Patients With Atrial Fibrillation
The purpose of this clinical research study is to determine whether apixaban is more effective than acetylsalicylic acid in the prevention of strokes associated with patients with atrial fibrillation.
- Trial name
- AVERROES (NCT00496769)
- Testing
- Apixaban, Acetylsalicylic acid
- Where
- 503 sites in United States, Argentina and 34 more
- Volunteers
- 6,421 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns, and safety and effectiveness outcomes in patients with NVAF…
- Trial name
- HELIOS-AF (NCT05038228)
- Testing
- Apixaban, Rivaroxaban, Dabigatran
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Pfizer
Nonvalvular Atrial Fibrillation
Safety and Efficacy of Apixaban in Very Old Geriatric Subjects (> 80 Years) With Atrial FIbrillation in a Prospective reAl World Study;
The main objective of this study is to realize an observational "real life" study conducted in French geriatric settings, to assess safety and efficacy in ≥ 80 year-old patients with nonvalvular Atrial fibrillation (AF) newly…
- Trial name
- SOFIA (NCT04586972)
- Where
- France
- Volunteers
- 977 people
- Sponsor
- Gérond'if
Cerebral Vein Thrombosis, Deep Vein Thrombosis
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
This randomized phase III trial studies the best dose of apixaban and how well it works in preventing secondary cancer related venous thrombosis in cancer patients who have completed anticoagulation therapy.
- Conditions
- Cerebral Vein Thrombosis, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT03080883
- Testing
- Apixaban
- Where
- 32 sites in United States
- Volunteers
- 370 people
- Sponsor
- Academic and Community Cancer Research United
Covid19, Corona Virus Infection
Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19
Since the end of 2019, Egypt and the whole world have been suffering from the Coronavirus Disease 2019 (COVID-19) pandemic, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Conditions
- Covid19, Corona Virus Infection, Hypercoagulability
- Trial name
- NCT04736901
- Testing
- Enoxaparin, Rivaroxaban, Apixaban
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Ain Shams University
Deep Vein Thrombosis, Pulmonary Embolism
Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein Thrombosis [DVT]) and lung (pulmonary embolism [PE]) that sometimes occur after knee replacement surgery and to learn how apixaban…
- Trial name
- NCT00371683
- Where
- 107 sites in United States, Argentina and 11 more
- Volunteers
- 3,608 people
- Sponsor
- Bristol-Myers Squibb
Transient Ischemic Attack, Stroke
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
The purpose of this study is to evaluate if Apixaban will decrease the complication of having another stroke for people who have atrial fibrillation if initiated earlier than standard of care.
- Conditions
- Transient Ischemic Attack, Stroke, Atrial Fibrillation
- Trial name
- AREST (NCT02283294)
- Testing
- Apixaban, Warfarin
- Where
- 5 sites in United States
- Volunteers
- 91 people
- Sponsor
- University of South Florida
Venous Thromboembolism, Major Bleed
Direct Oral Anticoagulants and Venous Thromboembolism
The purpose of this study is to determine whether use of direct oral anticoagulants (DOACs) is associated with an increased risk of major bleeding compared to warfarin use, for the treatment of venous thromboembolism (VTE).
- Trial name
- NCT02833987
- Testing
- Apixaban (ATC B01AF02), Dabigatran (ATC B01AE07), Rivaroxaban (ATC B01AF01)
- Where
- Canada
- Volunteers
- 59,525 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Acute Coronary Syndrome, Atrial Fibrillation
APixaban vs. PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF
It is hypothesised that a dual therapy strategy by oral anticoagulation with the new Factor-Xa-inhibitor apixaban plus clopidogrel is superior to a triple therapy regimen with phenprocoumon plus acetylsalicylic acid (ASA) and…
- Conditions
- Acute Coronary Syndrome, Atrial Fibrillation, Coronary Artery Disease
- Trial name
- APPROACH (NCT02789917)
- Testing
- Dual Therapy, Triple Therapy
- Where
- 16 sites in Germany
- Volunteers
- 403 people
- Sponsor
- LMU Klinikum
Venous Thromboembolism
Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants
This study is to evaluate the effects of multiple-dose clarithromycin on the single-dose pharmacokinetics (PK) of apixaban with parameters like Cmax, AUC(INF), and AUC(0-T).
- Trial name
- NCT02912234
- Testing
- Apixaban, Clarithromycin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation, Embolism Thrombosis
Assessment of The Effect of Apixaban in AF
This study will assess the effect of apixaban on thrombotic status in patients with atrial fibrillation.In addition it will compare apixaban to aspirin and warfarin on their effect on endogenous fibrinolysis.
- Trial name
- NCT03199521
- Testing
- Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)
- Where
- United Kingdom
- Volunteers
- 240 people
- Sponsor
- East and North Hertfordshire NHS Trust
Transcatheter Aortic Valve Replacement
Anticoagulation Alone Versus Anticoagulation and Aspirin Following Transcatheter Aortic Valve Interventions (1:1)
The main objective of this study is to demonstrate that a single anticoagulant therapy is superior to a combination of anticoagulant and antiplatelet therapy on the net clinical benefit estimated at 12 months after a…
- Trial name
- AVATAR (NCT02735902)
- Testing
- Vitamin K antagonist or direct oral anticoagulant treatment, Aspirin
- Where
- 6 sites in France
- Volunteers
- 170 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Healthy
Food Effect Study For Apixaban Commercial Image Tablets
To evaluate the effect of food on the pharmacokinetics of apixaban administered as commercial image tablets.
- Trial name
- NCT01437839
- Testing
- Apixaban
- Where
- Singapore
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Pfizer
Left Ventricular Thrombus
Apixaban in Patients With Left Ventricular Thrombus
Open label randomized controlled clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in treating left ventricular thrombus in patients with acute or recent myocardial infarction (MI).
- Trial name
- NCT05208398
- Testing
- Apixaban, Warfarin
- Where
- Saudi Arabia
- Volunteers
- 50 people
- Sponsor
- Saud Al Babtain Cardiac Center
Atrial Fibrillation
Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)
Apixaban is a direct anticoagulant, which inhibits the factor Xa. Its clinical efficiency in prevention of stroke and systemic embolism in adult patients with NVAF (non/valvular atrial fibrillation) was demonstrated as well as…
- Trial name
- SPAF (NCT03441633)
- Testing
- apixaban, dabigatran, VKA
- Where
- Spain
- Volunteers
- 51,690 people
- Sponsor
- Pfizer